

This is an Education Platform

We provide Free PDF Notes and Videos Classes for Pharmacy Students

Web Site http://www.fdspharmacy.in/

You tube https://www.youtube.com/channel/UC77iEsiuZolU4pB8WAJIR5Q

What app https://chat.whatsapp.com/IzSgXtFEvhS4LN5xhUgq5z

Telegram https://t.me/+cvxmi7xSloA4MjVl

Face book <u>https://www.facebook.com/Fdspharmacy-105764311994440/</u>

E-mail fdspharmacyinfo@gmail.com



Diploma in Pharmacy 2nd Year Hospital & Clinical Pharmacy Experiment

To fill up IPC's ADR reporting form and perform causality assessments using various scales.

Aim:

To fill up IPC's ADR reporting form and perform causality assessments using various scales.

Reference :

⁶ Dr. Gupta G.D. , Dr. Sharma Shailesh, Dr. Sharma Anshu, "Practical Manual of Hospital & Clinical Pharmacy" Published by Nirali Prakashan, Page no 13 - 18

Theory:

Suspected Adverse Drug Reaction Reporting Form

For documenting adverse drug reactions, the NCC has designed a "Suspected Adverse Drug Reaction Reporting Form". There are several forms for recording adverse reactions to blood transfusions, blood-related products, and Adverse Event Following Immunization (AEFD)

ICSR is a report that includes details about a suspected Adverse Drug Reaction (ADR) associated with the administration of one or more medications to a specific patient. The points listed below should be completed on an ADR form:

A) Patient Information

1) **Patient Initials**: The initials of a patient should be written instead of full name. For example, Madhu Gupta should be written as MG.



- 2) Age at Time of Event or Date of Birth: Either the date of birth or age of the patient should be written when the event or reaction has occurred.
- 3) **Sex:** The gender of the patient should be mentioned.
- 4) Weight: The weight of the patient should be mentioned.

B) Suspected Adverse Reaction

- 5) **Date of Reaction Started:** The date on which the reaction initially appeared should be mentioned
- 6) **Date of Recovery:** If the reaction recovered, the patient's recovery date from the reaction should be reported.
- 7) Describe Reaction: Description of the reaction, including its type. location, etc. should be provided. For example, an erythematous maculopapular rash appeared on the patient's upper and lower limbs.

C) Suspected Medications

- 8) The reporter should provide information about any suspected medications, including the drug name (brand or generic name), manufacturer, batch number or lot number, expiry date, dose used, route of administration, frequency, dates of therapy started and ended, and indication.
- 9) **Dechallenge Details:** The status on dechallenge should be mentioned as:
 - i) 'Yes': If the reaction subsides after dechallenge
 - ii) 'No': If the reaction does not subsides after der hallenge
 - iii) 'Unknown': If effect of dechallenge is not known.
 - iv) "Not Applicable' or 'NA': When dechallenge is unnecessary, as it is when it comes to things like vaccines, anaesthesia, the delivery of only one dose, patient death, or the end of therapy before a reaction or occurrence.
 - v) '**Reduced Dose':** If dose at which the reaction occurred is reduced?

Note: Reduced dose and date should also be mentioned

- 10) **Re-challenge Details:** The status on re-challenge should be mentioned as
 - i) **'Yes':** If reaction reappeared after re-challenge.
 - ii) 'No': If reaction does not reappear after re-challenge.
 - iii) 'Unknown': If effect of re-challenge is not confirmed.
 - iv) Not Applicable' or 'NA': If re-challenge is not applicable as in case of anaphylaxis reaction.
 - v) **Re-Introduced Dose':** Mention the dose and date of rechallenge The dose and date or re-challenge should be mentioned.
 - 11) **Concomitant Drugs:** The details of all concurrent drugs including self- medication, OTC medication, herbal remedies with therapy dates should be recorded.
 - 12) **Relevant Tests/Laboratory Data:** All the laboratory data (if available) that are related to the reaction should be mentioned.
 - 13) **Other Relevant History:** The related history of patient including pre- existing medical condition (such as, allergies, pregnancy, smoking. alcohol use, hepatic/renal dysfunction) and concurrent condition should be noted.
 - 14) **Seriousness of the Reaction:** The relevant cause for seriousness should be marked if any reaction is serious in nature:
 - i) 'Death': If a negative incident caused the patient's death Note: The cause and date of the death should be mentioned in the seriousness of the reaction.
 - ii) **'Life-Threatening':** If the patient was at serious risk of dying when the adverse event occurred.
 - iii) 'Hospitalisation/Prolonged': If the adverse event extended the patient's hospital stay or caused hospitalisation.



- iv) 'Disability': If adverse event caused a person's ability to carry out regular living functions to be significantly disrupted.
- v) **'Congenital Anomaly':** If taking drugs during or before would have harmed the unborn child. pregnancy
- vi) 'Required Intervention to Prevent Permanent Impairment/Damage': If a body function or structure needed to be protected against permanent impairment through medical or surgical intervention
- vii) 'Other': When the conditions do not fulfil the criteria above, yet it could still be dangerous for the patient and require a surgical or medical procedure to avoid one of the above conditions.
 For example, severe blood dyscrasias (blood disorders), non-hospitalised seizures or convulsions, the emergence of drug dependence, or drug addiction.
- 15) **Outcomes:** The outcome of the event should be marked:
 - i) 'Fatal': If the patient dies
 - ii) '**Continuing':** If the patient is continuing to experience the reaction.
 - iii) '**Recovering**': If the patient is recovering from the reaction.
 - iv) '**Recovered':** If the patient has completely recovered from the reaction (mention the date of recovery).
 - v) '**Unknown**': If the outcome is not known.

D) Reporter

- 16) **Name and Professional Address**: The patient name and address should be mentioned on the form by the reporter. The identity of the reporter should be maintained
- 17) **Causality Assessment:** If trained, the reporter should determine the causality and support the determination.



18) **Date of Report:** The date on which he/she reported the adverse event should be mentioned.

All the required information should be collected to fill in suspected ADR reporting form. All the Essentially Required Items (ERI) should be filled for quality ICSR if complete information is not available. It should be ensured that the form must include all the mandatory fields if ERI is not available.

Mandatory Fields	Es <mark>sentially Require</mark> d Items
Initials of the patient, age at response	Patient initials, age at onset of reaction.
onset, reaction term(s), and date of	gend <mark>er, reaction term(s), dat</mark> e of onset
reaction onset, suspected medication,	of reaction, suspected medication(s),
and reporter s details should be filled.	dose. d <mark>ate of therapy sta</mark> rted,
	indication of use, seriousness,
	outcome, dechallenge and rechallenge
	details, reporter's information and date
	of report should be filled.

Note: For a valid case report mandatory fields are the minimum requirement

earn and Educate



S.No. 8. Name (Brand/Generic) Manufacturer No. (if known) (Brand/Generic) /Lot No. (if known)	C. Suspected Medication(S)			7. Describe reaction or problem	6. Date of recovery (dd/mm/yyyy)	5, Date of reaction started (dd/mm/yyyy)	B. Suspected Adverse Reaction	ate of Birth 4. Weight	A. Patient Information	Report Type Initial Follow up	Sector-23, Raj Nagar, Ghaziabad-201002	(National Coordination Centre-Pharmacovigilance Programme of India)	For VOLUNTARY Reporting of Adverse Drug Reaction Reporting
used Route Frequency Therapy dates Indication used (OD, BD Date Date etc.) started stopped		□ Recovered □ Recovering □ Not □ Fatal □ Recovered with sequeted Unk	14. Seriousness of the reaction: No □ if Yes □ (please tick anyone) □ Death (dd/mm/yyyy) □ Congenital-anomaly □ Life threatening □ Required intervention to □ Hospitalisation/Prolonged Prevent permanent □ Disability □ Other (specify)		o	Smoking, alcohol use, henatic/renal dysfunction atc.)	12 Belance P W P A A	er kgs kgs	12 Believe No.:	Worldwide II-:	AMC Report No.:	ia) For AMC/NCC Use Only	For VOLUNTARY Reporting of Adverse Drug Reactions hv Healthcare Drofessional
Causality Assessments	The second second	Not recovered Unknown	ick anyone) i to			ce, pregnancy,	and the set						

n (please tick) n (ple	No 9. Action Taken (please tick). Io. Reaction reappeared after reintroduction (please tick). r C Unknown Yes No Effect Dose increased r C withdrawn Dose increased Dose increased changed applicable Unknown Yes No r C withdrawn Nos Dose increased Dose increased Dose (if nose) Dose (if nose) r C withdrawn Yes No Effect Dose (if nose) r Drug No No Yes No Effect Dose (if nose) r Drug No None (Brand/Generic) Dose used Route used Route used Proc.) Date started Date stoped No Name (Brand/Generic) Dose used Route used Route used Route used No No Name (Brand/Generic) Dose used Route used Route used Dose (if Name) No Name (Brand/Generic) Dose used Route used Route used Route used No Name (Brand/Generic) Dose used Route used Dose used Route used No Name (Brand/Generic) Dose used Route used Route used Route used No No	No 9. Action Taken (please tick). 10. Reaction reappeared after reintroduction (please tick). rC Drug Dose increased Dose not Not Ves No rC withdrawn Dose increased changed applicable Unknown Yes No Unknown reintroduction (please tick). rC withdrawn Dose increased changed applicable Unknown Yes No Unknown Pose (if reintroduction Mone Brand/Generic) Dose used Roure used Roure used Frequency (OD). Therapy dates (Exclude those used to treat reaction). Konconnitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction). Indication Konconnitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction). Indication Konconnitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction). Indication Konconnitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction). Indication Mone Name (Brand/Generic) Dose used Rout with Self Indication	No 9. Action Taken (please tick) Drug Dose increased withdrawn Dose increased Concomitant medical product including								
In (please tick) IO. Reaction reappeared after reintroduction (please tick) Dose increased Dose not Not Unknown Yes No Effect Dose increased changed applicable Unknown Yes No Effect In product increased changed applicable Unknown Yes No Effect In product increased changed applicable Unknown Yes No Effect In product increased changed applicable Unknown Yes No Effect In product increased changed applicable Unknown Yes No Internovn In product increased pose used Route used Frequency (OD, Therapy dates Internov (Generic) Dose used Route used BD, etc.) Date started Date stopped In transitional dates Dose used Route used Internov (OD, Therapy dates In transitional Dose used Route used BD, etc.) Date started Date stopped In transitional Dose used Route used Internov (OD, Therapy dates Internov In transitional Dose used Route used Internov (OD, <td< th=""><th>No 9. Action Taken (please tick). 10. Reaction reappeared after reintroduction (please tick). rC Viuhdravan Dose Dose Dose Dose Dose (rf rC viuhdravan Dose increased Dose Dose Dose (rf Dose (rf rC viuhdravan Dose increased Dose used changed applicable No Effect Dose (rf rC viuhdravan Ves No Fectured (rf Action Taken) Effect Dose (rf rC Viuhdravan Dose (rf applicable Action terapeared after reintroduction (please tick) rC Viuhdravan Dose (rf Action terapeared Dose (rf Dose (rf Concomitant medical product including self-medication and herbal ternedies with therapy dates (Exclude those used to teat reaction) Indication No Name (Brand/Generic) Dose used Route used Fequency (OD, Rest (rf Therapy dates ditional Information: Actional function: BD, etc.) Date started Date stopped Indication ditional Information: Information: Information: Information: Information: Information:</th><th>No 9. Action Taken (please tick) 10. Reaction reappeared after reintroduction (please tick) rC Vinhdrawn Dose increased Dose not No Unknown Yes No Dose (if rC vinhdrawn Dose increased coloced changed applicable Inknown Yes No Effect Dose (if rC vinhdrawn Dose increased coloced changed applicable Inknown Yes No Effect Dose (if rC Vinhdrawn Dose increased Rouce clanged applicable Inknown Yes No Inknown Dose (if Do</th><th>No 9. Action Taken (please tick) r C Drug Dose increased withdrawn Dose increased Concomitant medical product including</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></td<>	No 9. Action Taken (please tick). 10. Reaction reappeared after reintroduction (please tick). rC Viuhdravan Dose Dose Dose Dose Dose (rf rC viuhdravan Dose increased Dose Dose Dose (rf Dose (rf rC viuhdravan Dose increased Dose used changed applicable No Effect Dose (rf rC viuhdravan Ves No Fectured (rf Action Taken) Effect Dose (rf rC Viuhdravan Dose (rf applicable Action terapeared after reintroduction (please tick) rC Viuhdravan Dose (rf Action terapeared Dose (rf Dose (rf Concomitant medical product including self-medication and herbal ternedies with therapy dates (Exclude those used to teat reaction) Indication No Name (Brand/Generic) Dose used Route used Fequency (OD, Rest (rf Therapy dates ditional Information: Actional function: BD, etc.) Date started Date stopped Indication ditional Information: Information: Information: Information: Information: Information:	No 9. Action Taken (please tick) 10. Reaction reappeared after reintroduction (please tick) rC Vinhdrawn Dose increased Dose not No Unknown Yes No Dose (if rC vinhdrawn Dose increased coloced changed applicable Inknown Yes No Effect Dose (if rC vinhdrawn Dose increased coloced changed applicable Inknown Yes No Effect Dose (if rC Vinhdrawn Dose increased Rouce clanged applicable Inknown Yes No Inknown Dose (if Do	No 9. Action Taken (please tick) r C Drug Dose increased withdrawn Dose increased Concomitant medical product including								
In (please tick) In (please tick) In (please tick) Dose increased Teduced Toologe the point of t	No 9. Action Taken (please tick) 10. Reaction reappeared after reintroduction (please tick) r C withdrawn Dose increased reduced changed applicable Unknown Yes No Effect Dose (if r C withdrawn Dose increased reduced changed applicable Unknown Yes No Effect Dose (if r C withdrawn Yes No Effect Dose (if Dose (if r Concomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction) Indication Concomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction) Indication Konomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction) Indication Konomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction) Indication Konomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction) Indication Konomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction) Indication Konomitant medical product including the self-medication and herhal remedies with therapy dates Indication	No Action Taken (please tick) 10. Reaction reuppeared after reintroduction (please tick) rC Ubrug Dose increased Dose not Not Effect Dose (if rC withdrawn Dose increased changed applicable Unknown Yes No Effect Dose (if rC withdrawn Dose increased changed applicable Unknown Yes No Effect Dose (if No Name (Brand/Genetric) Dose used Route used Frequency (OD. Therapy dates Indication No Name (Brand/Genetric) Dose used Route used Frequency (OD. Therapy dates Indication Mitomal Information:	No 9. Action Taken (please tick) Drug Dose increased r C withdrawn 0 e increased								
applicable I0. Reaction reappeared after reintroduction sed Dose not Not Unknown Yes No Effect reduced changed applicable Innknown Yes No Effect uding self-medication and herbal remedies with therapy dates (Exclude those used Frequency (OD, Therapy dates (Exclude those used to treat reaction) Dose used Route used BD, etc.) Date started Date stopped Pin: E-mail Fiel. No. (with STD code) Tel. No. (with STD code)	No 9. Action Taken (please tick) 10. Reaction reappeared after reintroduction (please tick) rC brug Dose increased Dose Dose not Not Unknown Yes No Effect Dose (if reduced changed changed applicable Unknown Yes No Effect Dose (if No methor reduced changed changed changed changed applicable bose (if Dose (if Do	In (please tick) Dose increased after reintroduction (please tick) Dose increased reduced changed applicable Not Ves No Effect reduced changed applicable Not Ves No Effect reduced changed applicable Dose used to treat reaction. If product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) (Generic) Dose used Route used Frequency (OD, Therapy dates (Exclude those used to treat reaction) (Generic) Dose used Route used Frequency (OD, Date started Date stopped Date stopped	No 9. Action Taken (please tick) Drug Dose increased withdrawn Dose increased								
Dose increased Dose increased Dose increased Dose unknown Yes No Effect reduced changed applicable http://withinteraprocesconsection http://withinteraprocesconsection http://withinteraprocesconsection If product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) ftequency (OD, Therapy dates (Exclude those used to treat reaction) (Generic) Dose used Route used BD, etc.) Date started Date stopped // for the interaption interaprocesconsection interaprocesconsection interaprocesconsection	Clication Dose increased Dose not Not Unknown Yes No Effect Dose (if Nuthdrawn reduced changed applicable applicable how Yes how reintroduced No Name (Brand/Generic) Dose used Route used Route used Frequency (D). Therapy dates Indication No Name (Brand/Generic) Dose used Route used Route used BD, etc.) Date started Date stopped Indication No Name (Brand/Generic) Dose used Route used Route used Frequency (OD, Therapy dates Indication No Name (Brand/Generic) Dose used Route used Route used Frequency (OD, Therapy dates Indication No Name (Brand/Generic) Dose used Route used Route used Frequency (OD, Therapy dates Indication No Name (Brand/Generic) Dose used Route used Indication Date started Date stopped Indication Alional Information:	Cling Dose increased Entitroduced)	r C Drug Dose increased withdrawn Dose increased Concomitant medical product including					10. Reaction	n reappeare	d after reintroduc	tion (please tick)
Interview Interview Interview Interview Interview Interview	Image: Note of the set of t	Interpret in the interpret of the interpret i	Concomitant medical product including	Dose reduced	Dose not changed	Not applicable	Unknown	Yes	No	Effect unknown	Dose (if reintroduced)
Il product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) /Generic) Dose used Route used Frequency (OD, Therapy dates BD, etc.) Date started Date stopped Date started Date stopped D. Reporter Details I. 6. Name and Professional Address: Detail Tel. No. (with STD code) Signature:	Name (Brand/Generic) Dose used Route used Frequency (OD, Name (Brand/Generic) Indication Vo Name (Brand/Generic) Dose used Route used Frequency (OD, BD, etc.) Therapy dates Indication Vo Name (Brand/Generic) Dose used Route used BD, etc.) Date started Date stopped Indication BD, etc.) Date started Date stopped Indication Information:	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Indication Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Indication Vo Name (Brand/Generic) Dose used Route used Frequency (OD, Therapy dates Indication Model BD, etc.) Date started Date stopped Indication Itional Information:	Concomitant medical product including						·		
International product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Generic Dose used Route used Frequency (OD, BD, etc.) Generic Dose used Route used BD, etc.) Date started Date started Date stopped International International Address: International Address:	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Vo Name (Brand/Generic) Dose used Route used Frequency (OD, Route used Frequency (OD, BD, etc.) Indication Vo Name (Brand/Generic) Dose used Route used Route used BD, etc.) Date started Indication Indication BD, etc.) Date started Date stopped Indication Information: Information: Information: Information: Information: Information: Information: Information: Information: Information:	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) No Name (Brand/Generic) Dose used Route used Frequency (OD, BD, etc.) No Name (Brand/Generic) Dose used Route used Frequency (OD, BD, etc.) Therapy dates Indication BD, etc.) Date started Date stopped Indication: Date started Date started Date stopped Indication: Date started Date started Date stopped Indication: Date started Date started Date started Indication: Date started Date started Date stopped Indication: Date started Date started Date started Indication: Date of t	Concomitant medical product including								
If product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Generic) Dose used Route used Frequency (OD, Therapy dates BD, etc.) Date started Date stopped Date started Date stopped Date started Date stopped 16. Name and Professional Address: Tel. No. (with STD code) Signature: Occupation:Signature:	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Vo Name (Brand/Generic) Dose used Route used Frequency (OD, Therapy dates (Exclude those used to treat reaction) Nome (Brand/Generic) Dose used Route used Route used ED, etc.) Date started Date stopped Indication Indicat	Concomitant medical product including self-medication and herhal remedies with therapy dates (Exclude those used to treat reaction) Indication Vo Name (Brand/Generic) Dose used Route used Frequency (OD, Route used Frequency (OD, Route used Indication Indication BD, etc.) Date started Date stopped Indication Information: Information: Indication Indication Indication Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Infor	Concomitant medical product including								
If product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) A Generic) Dose used Route used Frequency (OD, Therapy dates BD, etc.) Date started Date stopped Date stored Date stopped Date started Date stopped Date stored Date stopped Date stored Date	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) No Name (Brand/Generic) Dose used Route used Frequency (OD, BD, etc.) Therapy dates Indication No Name (Brand/Generic) Dose used Route used Frequency (OD, BD, etc.) Therapy dates Indication Information: D. Reporter Otal Date started Date stopped Date stopped Indication ditional Information: I. Reporter Details I. Reporter Details I. No. (with STD code) Indication fittional Information: I. No. (with STD code) I. No. (with STD code) Indication	Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction) Vo Name (Brand/Generic) Dose used Route used Frequency (OD, Therapy dates Indication vio Name (Brand/Generic) Dose used Route used Frequency (OD, Therapy dates Indication diftional Information:	Concomitant medical product including								
/Generic) Dose used Route used Frequency (OD, BD, etc.) Therapy dates BD, etc.) Date started Date stopped IG IG None and Professional Address: Pin: F-mail Tel. No. (with STD code) Occupation: Signature:	Name (Brand/Generic) Dose used Requency (OD, BD, etc.) Therapy dates Indication Initional Information: BD, etc.) Date started Date stopped Indication Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information: Information:	Vol Name (Brand/Generic) Dose used Route used Frequency (OD, BD, etc.) Therapy dates Indication iftional intervalue intervalue intervalue intervalue indication iftional intervalue intervalue intervalue indication indication iftional information: intervalue intervalue indication indication iftional information: intervalue intervalue intervalue indication iftional information: intervalue intervalue indication indication iftional information: intervalue intervalue intervalue indication iftional information: intervalue intervalue intervalue indication iftional information: intervalue intervalue intervalue indication iftional intervalue intervalue intervalue intervalue intervalue iftional intervalue intervalue intervalue intervalue intervalue iftional intore interva		r self-medica	tion and herba	I remedies with	th therapy da	ates (Exclude t	hose used t	treat reaction)	
Date started	Date started Date started Date stopped Information: D. Reporter Details	Date started Date started Date stopped fitional Information: D. Reporter Details Date stopped fitional Information: D. Reporter Details D. Reporter Details	Name (Brand/Generic)	ose used	Route used	Frequency BD, etc	(OD,	Ther	apy dates		Indication
D. Reporter Details 16. Name and Professional Address: Fin: E-mail Occupation:	litional Information: Informa	litional Information: If it is not expected to the fullest extent. Programme staff is not expected to and will not d If it is not expected to the fullest extent. Programme staff is not expected to and will not d reporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf						Date started	Date	stopped	- m -
D. Reporter Details D. Reporter Details 16. Name and Professional Address: Pin: Fin: Tel. No. (with STD code) Occupation:	litional Information: D. Reporter Details D. Reporter Details 16. Name and Professional Address: 17. No. (with STD code) Signature: 17. Date of this report (dd/mm/yyy):	fitional Information: Information: Information: Informati					No. of Contraction of				
D. Reporter Details 16. Name and Professional Address: Pin: F-mail Tel. No. (with STD code) Occupation:	Iftional Information: D. Reporter Details 16. Name and Professional Address: 17. Date of this report (dd/mm/yyyy):	If it on a ln formation: D. Reporter Details If and Professional Address: If and Professional Address: If a number of this report (dd/mm/yyyy): If a number of this report (dd/mm/yyyy): If a number of a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf					A VALLE	5 6	A. I.		
16. Name and Professional Address: Pin: E-mail Tel. No. (with STD code) Occupation:	16. Name and Professional Address: 16. Name and Professional Address: Pin: E-mail Pin: E-mail Pin: Decempation: Occupation: Signature: 17. Date of this report (dd/mm/yyyy):	I6. Name and Professional Address: 16. Name and Professional Address: Pin: E-mail Pin: E-mail Tel. No. (with STD code) Signature: Occupation: Signature: 17. Date of this report (dd/mm/yyyy): I7. Date of this report (dd/mm/yyyy): reporter's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not d eporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf	ditional Information:	- 7 -		D.	Reporter D	etails		Sec. 1	
lail	Pin: E-mail Tel. No. (with STD code)	Fin: E-mail Tel. No. (with STD code)				16.	Name and	Professional A	ddress:		
	Decupation: Signature: 0.0cupation: 0.0cupation: 17. Date of this report (dd/mm/yyyy):	Internation: Signature: Internation: Sidentity in res				-E	1: No (with	E-mail			
and	17. Date of this report (dd/mm/yyyy):	Ifdentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not d eporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf				0.00	cupation:		Si	gnature:	
17. Date of this report (dominy)	rest and will not a start artent Programme staff is not expected to and will not o	fidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not d eporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manuf				17.	. Date of thi	s report (dd/m	m/yyyy):		



Case Study

On 12.01.2016, 65-year-old Madan Lal was taken to the hospital after experiencing upper stomach pain and nausea for the last 5 days. A yellowish discoloration in the nail bed, conjunctiva, and hand was discovered during a physical examination. His weight was 72 kg.

He experienced a few psychotic attacks, for which he has been receiving chlorpromazine medication for the last four weeks. When questioned, he told that he was taking 4 Tab. of Largactil (Chlorpromazine) 100 mg pills before bed. Before being admitted to the hospital, he was also taking Tab. Diclofenac 50 mg twice day for three days due to gastrointestinal pain. On the day of admission, he was examined for the following laboratory parameters:

```
Alkaline Phosphatase = 180 U/L (Normal Range: 25-100 U/L)
ALT=205 U/L (Normal Range: 10-40 Units/L)
Total Bilirubin = 5.0 mg/dL (Normal Range: 0.8-1.2 mg/dL)
```

Treatment with Diclofenac and chlorpromazine was stopped on admission. The level of pain decreased after stopping the medication for 7 days. Additionally, he was re-examined for above parameters as indicated above: Alkaline Phosphatase = 110 IU/L ALT=98 Units/L Total Bilirubin = 1.8 mg/dL

Note: Tab Chlorpromazine Brand Manufacturer: Wedley labs 1 Batch number: LGL088

Name:

LARGACTIL,

Expiry date: Dec 2018



A. Patient Information

- Patient Initials ML 1
- Age at the time of Event or Date of Birth-65 years 2
- Sex 3 Male

Female

Other

Weight (kg)-72 kg 4

B. Suspected Adverse Reaction

- Date of Reaction started (dd/mm/yyyy): 07.01.2016 5
- 6 Date of recovery (dd/mm/yyyy):
- Describe reaction or problem
- Patient was taking Chlorpromazine since 12.12.2015 He developed pain in abdomen 7 And nausea since 07.01 2016. Examination revealed yellowish discoloration of conjunctiva, palm and nails Patient was admitted on 12.01.2016 and investigated. Live function tests indicated raised serum bilirubin, ALT and alkaline phosphatase Drugs were discontinued. On discontinuation of drug, reaction subsided in one week

C. Suspected Medication

- Name (Brand and/or Generic): Tab. Chlorpromazine (Largactil)
- 8 Manufacturer (if known): Wedley labs Batch No/Lot No: LGL0881 Exp. Date (if known): Dec 2018 Dose used: 400 mg Route used: Oral Frequency (OD, BD, etc): OD Therapy dates Date Started 12.12.2015 Date Stopped 12.01.2016 **Indication:** Psychosis
 - **Causality Assessment: Probable**



Yes	No	ed after	e reduced reintroduct Effect unkn	Dose not changed ion (please to own	Not applicable tick) Dose (if reints	Unknown roduced)
eaction r Yes	No			A REPORT OF THE	ick) Dose (if reintr	roduced)
Yes	No			A REPORT OF THE	ick) Dose (if reinti	roduced)
Yes	No			A REPORT OF THE	ick) Dose (if reinti	roduced)
Yes	No			A REPORT OF THE	tick) Dose (if reintr	roduced)
Yes	No			A REPORT OF THE	bick) Dose (if reinti	roduced)
Yes	No			A REPORT OF THE	Dose (if reint	roduced)
	and share					1.4
	1100	dan gi	and the first			
			1 A. 1 . 1			
	1.1.8					
		1 - 1	1-1 (314)-	ETCL - APPEND	Harth Cold Hart	
	lf-medicat	ion and he	erbal remedie	s with therapy	6 martine	
Name	Dose	Route	Frequenc			Indication
Contraction of the State of the	used	Used	and the second sec	Date	COLOR DATE:	
			1			Pain in
Diclofena	50 mg	Oral	BD	6	6	abdomen
č						
						1
						-
2.01.2016 Alkaline P J/L ALT = 205 Fotal Bilir Relevant I	6 Phosphata 5 U/L ubin = 5.0 medical/r	se = 180) mg/dL nedicati	19.01.20 Alkaline ALT = 9 Total Bi on history	916 9 Phosphatas 98 U/L 1 lirubin = 1.8	mg/dL	
etc.)			ncy, smokir	ig, alcohol u	se, hepatic/rei	nal dysfunctio
No Death (dd/	If /mm/yyyy	yes		(Please tick	anyone)	
Hospitalisa Disability Congenita Required i	ation (init l anomaly nterventio	,		nent impairm	ient/damage	
	Name Brand/G eneric) Tab. Diclofena c Relevant f 2.01.2010 Alkaline F J/L ALT = 20: Total Bilir Relevant f e.g. allerg otc.) Seriousness No Death (dd/ Life threat Hospitaliss Disability Congenita Required i	Name Dose Brand/G used Tab. 50 mg Diclofena c C So mg Relevant tests/labo 2.01.2016 Alkaline Phosphata J/L ALT = 205 U/L Cotal Bilirubin = 5.0 Calevant medical/r e.g. allergies, race, stc.) Seriousness of the r If Death (dd/mm/yyyy) Life threatening Hospitalisation (init) Disability Yongenital anomaly Congenital anomaly	Name Brand/G eneric)Dose usedRoute UsedTab. Diclofena c50 mgOralTab. Diclofena c50 mgOralRelevant tests/laboratory G 2.01.2016Alkaline Phosphatase = 180 J/LALT = 205 U/L Cotal Bilirubin = 5.0 mg/dL Relevant medical/medicati e.g. allergies, race, pregnatic.)Seriousness of the reaction: NoIf yes Death (dd/mm/yyyy) Life threatening Hospitalisation (initial or pro Disability Congenital anomaly Required intervention to pre	Brand/GusedUsedy (OD, BD, etc.)Tab.50 mgOralBDDiclofenacIIcIIIRelevant tests/laboratory data with da19.01.20Alkaline Phosphatase = 180AlkalineJ/LALT = 9ALT = 205 U/LTotal BiTotal Bilirubin = 5.0 mg/dLRelevant medical/medication historye.g. allergies, race, pregnancy, smokinitoutIf yesIDeath (dd/mm/yyyy)Life threateningHospitalisation (initial or prolonged)DisabilityCongenital anomalyRequired intervention to prevent permar	Name Brand/GDose usedRoute UsedFrequenc y (OD, BD, etc.)Therap Date StartedTab. Diclofena c50 mgOralBD09.01.201 6CImage: StartedImage: Started6CImage: StartedImage: Started1mage: StartedCImage: StartedImage: Started1mage: Started </td <td>Name Brand/G eneric)Dose usedRoute UsedFrequenc y (OD, BD, etc.)Therapy dates DateTab. Diclofena c50 mgOralBD09.01.20112.01.201Tab. c50 mgOralBD09.01.20112.01.201Caab666Caab10.01.20166Caaba10.01.20166Caaba10.01.20166Caaba10.01.201610.01.2016Alkaline Phosphatase = 180Alkaline Phosphatase = 110 U/L ALT = 98 U/LAAA10.01.2016Alkaline Phosphatase = 180Alkaline Phosphatase = 110 U/L ALT = 98 U/LAA10.01.2016Alkaline Brosphatase = 5.0 mg/dLTotal Bilirubin = 1.8 mg/dLTotal Bilirubin = 1.8 mg/dLCotal Bilirubin = 5.0 mg/dLCaaaRelevant medical/medication history e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/reater.)aaSeriousness of the reaction: NoIf yes(Please tick anyone)aDeath (dd/mm/yyyy)baaaLife threatening Hospitalisation (initial or prolonged)aaaDisability Congenital anomaly Required intervention to prevent permanent impairment/damageaa</td>	Name Brand/G eneric)Dose usedRoute UsedFrequenc y (OD, BD, etc.)Therapy dates DateTab. Diclofena c50 mgOralBD09.01.20112.01.201Tab. c50 mgOralBD09.01.20112.01.201Caab666Caab10.01.20166Caaba10.01.20166Caaba10.01.20166Caaba10.01.201610.01.2016Alkaline Phosphatase = 180Alkaline Phosphatase = 110 U/L ALT = 98 U/LAAA10.01.2016Alkaline Phosphatase = 180Alkaline Phosphatase = 110 U/L ALT = 98 U/LAA10.01.2016Alkaline Brosphatase = 5.0 mg/dLTotal Bilirubin = 1.8 mg/dLTotal Bilirubin = 1.8 mg/dLCotal Bilirubin = 5.0 mg/dLCaaaRelevant medical/medication history e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/reater.)aaSeriousness of the reaction: NoIf yes(Please tick anyone)aDeath (dd/mm/yyyy)baaaLife threatening Hospitalisation (initial or prolonged)aaaDisability Congenital anomaly Required intervention to prevent permanent impairment/damageaa

Categories	Time Sequence	Other Drug Disease Ruled Out	Dechallenge	Rechallenge
Certain	Yes	Yes	Yes	Yes
Probable	Yes	Yes	Yes	No
Possible	Yes	No	No	No
Unlikely	No	No	No	No

Result :

IPC's ADR reporting form was filled and causality assessments using various scales was performed.

FDSPharmacy Learn and Educate



Hello	
Friends	
lf you Get A	ny Help From This Notes /
Videos	
Next You Tu	rn To Help Us
Please Cont	ribute Some Amount
To Our	
FDSPharmac	y Team
Phone Pe	6398439940
Paytm	6398439940
Google Pay	6398439940

Amir Khan



